Proteasome inhibitors in mantle cell lymphoma

Mantle cell lymphoma (MCL) represents a subtype of non-Hodgkin's lymphoma (NHL) which has a relatively poor prognosis compared to other forms of NHL. Despite multiple options for cytotoxic chemotherapy, attempts to prolong the survival of patients with this disease have not yet met with success...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Best practice & research. Clinical haematology 2012-06, Vol.25 (2), p.133-141
Hauptverfasser:	Holkova, Beata, MD, Grant, Steven, MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use Boronic Acids - administration & dosage Boronic Acids - therapeutic use Bortezomib carfilzomib Clinical Trials as Topic Combined Modality Therapy Drug Resistance, Neoplasm Hematology, Oncology and Palliative Medicine Humans Lymphoma, Mantle-Cell - metabolism Lymphoma, Mantle-Cell - mortality Lymphoma, Mantle-Cell - therapy mantle cell lymphoma non-Hodgkin's lymphoma Oligopeptides - administration & dosage Oligopeptides - therapeutic use Protease Inhibitors - administration & dosage Protease Inhibitors - therapeutic use proteasome inhibitor Proteasome Inhibitors - administration & dosage Proteasome Inhibitors - therapeutic use Pyrazines - administration & dosage Pyrazines - therapeutic use Recurrence Signal Transduction - drug effects Survival Analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!